Phase 3 SURPASS-ET data support the expanded indication of ropeginterferon alfa-2b-njft as the first new FDA-approved essential thrombocythemia therapy in nearly 3 decades.

Approval of the IL-12/23 antagonist in pediatric ulcerative colitis was supported by data from the phase 3 UNIFI Jr trial, demonstrating 52-week clinical remission and favorable tolerability.

Effective atrial fibrillation management requires rate or rhythm control, anticoagulation based on risk scores, and lifestyle ...

Mimrylo is the first subcutaneous hepcidin mimetic approved to control hematocrit levels and reduce phlebotomy burden in patients with polycythemia vera.

A healthy lifestyle in early childhood is associated with a reduced risk for inflammatory bowel disease (IBD), according to a study published online August 24 i ...

The researchers found that the adjusted mean percentage change in body weight at the 24-month follow-up was −3.40% for the Mediterranean-style intervention and −3.51% for the control intervention. The ...

The updated vaccines are expected to be available in pharmacies, hospitals, and clinics in the coming days. In May 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee ...

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...

HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in ...

Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver regeneration following surgical resection.

Bixlenvo demonstrated noninferiority to multi-tablet and 3-drug regimens in virologically suppressed adults with HIV-1, expanding single-tablet options for patients on complex regimens. The Food and ...